There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardant Health (GH – Research Report), IQVIA Holdings (IQV – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments.
Guardant Health (GH)
In a report released today, Anthony Stoss from Craig-Hallum maintained a Buy rating on Guardant Health. The company’s shares closed last Friday at $22.42, close to its 52-week low of $20.67.
According to TipRanks.com, Stoss is a 5-star analyst with an average return of
Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $43.33.
See the top stocks recommended by analysts >>
IQVIA Holdings (IQV)
Jefferies analyst David Windley maintained a Buy rating on IQVIA Holdings today and set a price target of $281.00. The company’s shares closed last Friday at $238.60, close to its 52-week high of $243.82.
According to TipRanks.com, Windley is a 5-star analyst with an average return of
Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $269.23, which is an 11.5% upside from current levels. In a report issued on February 14, Bank of America Securities also maintained a Buy rating on the stock with a $255.00 price target.
Ascendis Pharma (ASND)
Jefferies analyst Kelly Shi maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $174.00. The company’s shares closed last Friday at $156.39, close to its 52-week high of $156.44.
According to TipRanks.com, Shi is a 3-star analyst with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $174.60, a 20.3% upside from current levels. In a report issued on February 7, Goldman Sachs also maintained a Buy rating on the stock with a $170.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GH:
- Guardant Health Announces Board Member Samir Kaul’s Resignation
- Guardant Health price target lowered to $54 from $64 at Craig-Hallum
- Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
- Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
- Guardant Health reports preliminary Q4 revenue $153M-$154M, consensus $146.34M
